ABSTRACT

Background: Alteration in oxidative and nitrosative stress as well as antioxidant status is known to occur in carcinogenesis and during treatment of cancer with chemotherapeutic drugs.

Objective: The objective of this study was to evaluate the serum levels of reduced glutathione (GSH), glutathione-s-transferase (GST) and nitric oxide (NO\(^•\)) in post-operative stage II breast cancer patients undergoing adjuvant chemotherapeutic treatment.

Material and Methods: Clinically and histopathologically proven 30 stage II breast cancer patients were selected for the present study. Blood was collected after mastectomy before start of 1\(^{st}\) adjuvant chemotherapy cycle and 3 weeks after receiving 1\(^{st}\) cycle of chemotherapy. 30 healthy controls were selected for comparison. Serum GSH, GST and NO\(^•\) levels were estimated by spectrophotometric methods.

Results: The serum level of reduced glutathione was significantly lower (P<0.0004) whereas serum levels of GST and NO\(^•\) were significantly higher (P<0.0001) in post-operative stage II breast cancer patients before chemotherapy as compared to healthy controls. After 3 weeks of receiving 1\(^{st}\) adjuvant chemotherapy cycle, significant decrease in the serum levels of GSH, GST and NO\(^•\) was observed (P<0.0001) as compared to levels before chemotherapy in these patients. Significant positive correlation was found between GSH and NO\(^•\) (r=+0.96) and GSH and GST (r= +0.91) after chemotherapy.

Conclusion: The findings of the study suggests that administration of chemotherapeutic drugs in adjuvant setting in breast cancer patients causes increase in oxidative stress as indicated by decreased levels of antioxidant glutathione. The observed decrease in levels of GST and NO\(^•\) might be associated with decrease in levels of GSH in these patients after chemotherapy.

Keywords: Antioxidants, Oxidative stress, FEC, S-nitrosoglutathione.
cause damage to all major classes of biomolecules such as lipids, proteins and nucleic acids and causes changes in their structure and function. To combat the deleterious effects of these free radicals, cells have developed different antioxidant mechanisms consisting of enzymatic and non-enzymatic components. Reduced glutathione (GSH) is the most abundant thiol in cells which acts as an important antioxidant. GSH is capable of scavenging hydrogen peroxide and peroxynitrite. It may affect the bioactivity of NO•. It is the precursor of s-nitrosoglutathione (GSNO). GSNO can transnitrosate protein thiols, possibly changing protein functions. Glutathione-s-transferase (GST) is a ubiquitous multifunctional enzyme involved in detoxification. GST catalyze the conjugation of GSH to electrophilic species and plays a central role in the defense against free radicals, lipid hydroperoxides and detoxification of potential alkylating agents including anticancer drugs. Nitric oxide (NO•) is an inorganic free radical gas produced by nitric oxide synthase (NOS) using L-arginine. Nitric oxide (NO•) is a polyfunctional molecule that controls the variety of processes such as: vasodilatation, neurotransmission, immunocytotoxicity, carcinogenesis, induction or inhibition of apoptosis, etc. Furthermore, it is well known that NOS activity increases in some invasive tumors. The role of NO• in tumor biology is still poorly understood. Elevated levels of NO• provides primary source of reactive nitrogen species like peroxynitrite. Peroxynitrite which may be cytotoxic by itself is much more reactive and causes diverse chemical reactions in biological systems including nitration of tyrosine residues of proteins, triggering lipid peroxidation, inhibition of mitochondrial electron transport and oxidation of biological thiol compounds. Changes in the serum levels of nitric oxide (NO•), reduced glutathione (GSH) and glutathione-s-transferase (GST) have been reported previously in breast cancer patients. However, there is little research regarding the changes in these parameters after chemotherapy. Therefore, the present study was undertaken to evaluate the serum levels of nitric oxide, reduced glutathione and glutathione-s-transferase in post-operative stage II breast cancer patients receiving adjuvant chemotherapy treatment.

**MATERIAL AND METHODS**

30 female breast cancer patients diagnosed with invasive ductal/lobular carcinoma with stage II classified by Tumor-Node-Metastasis (TNM) system and proven by histopathological evidence were involved in this study. The patients were admitted in the Sassoon General Hospital, Pune [Maharashtra, India] and were of 30 - 75 years age (Mean age 52.5±13.42). 30 healthy and age matched female controls were selected for comparison.

The study was approved by Institutional Ethical Committee [Ref No. BJMC/IEC/Pharmac/D1210137-39]. After obtaining prior written consent from healthy volunteers and breast cancer patients, 5ml of venous blood was drawn under aseptic precautions after mastectomy before the start of chemotherapy and after three weeks of receiving 1st adjuvant cycle of 5-Flurouracil, Epirubicin, Cyclophosphamide (FEC) / Adriamycin (Doxorubicin), Cyclophosphamide (AC)/ Paclitaxel chemotherapy. The serum was separated and stored at -80 °C until analysis.

To avoid false positive results, care was taken to exclude subjects suffering from infectious diseases, allergic diseases, hepatic disorders, cardiac disorders, autoimmune diseases, systemic diseases such as diabetes and other malignancies. The required chemicals- Reduced glutathione, 1-chloro-2, 4-dinitrobenzene (CDNB) and 5-5'-
Dithiobis, 2-nitrobenzoic acid (DTNB) were purchased from Alfa Aesar, South Korea.

**Measurement of Reduced glutathione (GSH)**
GSH content of serum was determined by the method of Moron et al. GSH was determined by the use of standard curve and was expressed as mg/dl.

**Measurement of Glutathione-s-transferase (GST)**
Serum GST was estimated by CDNB method. GST values were expressed as IU/L.

**Measurement of Nitric oxide (NO•)**
Serum NO• level was determined in terms of nitrate and nitrite by kinetic cadmium reduction spectrophotometric method with detection limits in serum of 2-250 µmol/L and CVs of 9% and 4.7% for nitrate concentrations of 31.4 µmol/L and 80.2 µmol/L respectively. NO• values were expressed as µmol/L.

**Statistical analysis**
The data for biochemical analysis was expressed as Mean ± SD. The statistical significance of the results was analyzed by using one-way ANOVA and Student's t test. Values of P<0.05 were considered significant. Bivariate correlation was used to analyze the relation between these parameters before and after chemotherapy.

**RESULTS**
Table A.1 shows the mean serum levels of reduced glutathione, glutathione-s-transferase and nitric oxide in healthy controls and stage II breast cancer patients before and after adjuvant chemotherapy. The serum levels of reduced glutathione were significantly lower in post-operative breast cancer patients before chemotherapy (group II) as compare to healthy controls (group I) (P<0.0001). Further significant decrease in the levels was observed in breast cancer patients after 3 weeks of receiving 1st adjuvant chemotherapy cycle (group III) as compare to levels before chemotherapy (group II) (P<0.0001) but the levels were still significantly higher as compare to healthy controls (group I) (P<0.0001). The serum levels of nitric oxide were found significantly higher in post-operative breast cancer patients before chemotherapy (group II) as compare to healthy controls (group I) (P<0.0001). But the levels were decreased significantly in breast cancer patients after 3 weeks of receiving 1st adjuvant chemotherapy (group III) as compare to levels before chemotherapy (group II) (P<0.0001) and as compare to levels in healthy controls (group I) (P<0.0001). Using bivariate correlation analysis of the measured parameters, we found a significantly inverse correlation between GSH and NO• (r= -0.95) before chemotherapy and significant positive correlation between serum levels of GSH and NO• (r=+0.96) and GSH and GST (r=+0.91) after chemotherapy.

**DISCUSSION**
In the present study, to assess the effect of adjuvant chemotherapy on serum levels of GSH, GST and NO• we have investigated serum levels of these parameters post-operatively in stage II breast cancer patients before start of chemotherapy and after 3 weeks of receiving 1st cycle of adjuvant chemotherapy.

Adjuvant chemotherapy is widely used systemic treatment for breast cancer patients after surgical removal of tumor. Many reports have demonstrated that the anticancer drugs of different classes are known to generate a high level of oxidative stress in biological systems. Free radical generation is controlled by antioxidant systems that act as protection against
free radicals. The glutathione and glutathione dependent enzymes can directly scavenge free radicals and protects cells from oxidative insults. Reduced glutathione also acts as substrate for GST during detoxification of electrophilic compounds. In the present study, we have observed significantly lower levels of GSH in post-operative breast cancer patients before undergoing adjuvant chemotherapy as compare to healthy controls (P<0.0004). The decreased levels of GSH after surgery have been reported in patients with gastric cancer. However, in contrast to our finding, elevated levels of GSH in breast cancer patients and non-significant decrease in the levels after 3 weeks of mastectomy have also been reported. We found a significant inverse correlation between levels of GSH and nitric oxide in post-operative stage II breast cancer patients before chemotherapy (r=-0.95). The lower levels of GSH after surgery and before chemotherapy may be associated with higher levels of NO before chemotherapy that causes increase in formation of peroxynitrite and further oxidation of GSH or it may be possible that GSH could be utilized in the formation of GSNO to neutralize radical NO. GSH may also be utilized in the detoxification of lipid hydroperoxides that are formed because of high oxidative and nitrosative stress. After 3 weeks of administration of 1st adjuvant chemotherapy cycle, we found further significant decrease in serum levels of GSH as compare to levels before chemotherapy (P<0.0001) and as compare to levels in healthy controls (P<0.0001). This is in agreement with the previous study reports. The metabolism of antineoplastic drugs produces highly reactive electrophiles and oxidative stress. Thus produced oxidative stress by antineoplastic drugs is counterbalanced by various antioxidants of the body. GSH is one of the major antioxidant and this high oxidative stress might result in reduction in its levels after chemotherapy. Glutathione-s-transferase catalyses conjugation of GSH with highly reactive electrophiles and thereby plays an important role in detoxification of chemotherapeutic drugs. High concentrations of GST may rapidly detoxify anticancer agents and thus prevents their cytotoxic action. In this study, we found significantly higher values of GST in stage II of breast cancer patients post-operatively before chemotherapy as compare to healthy controls (P<0.0001). This is in agreement with previous study reports. The level of GST in serum is found to be elevated in most of the human cancers studied and is induced upon oxidative stress. The higher values were observed post-operatively because normalization of GST levels after surgery may take about a month. Further, we found significant decrease in the serum levels of GST after 3 weeks of receiving 1st cycle of adjuvant chemotherapy as compare to levels before chemotherapy (P<0.0001) but the values were still significantly higher as compare to healthy controls (P<0.0001). Similar findings were reported by Chakraborty et al. We found a significant positive correlation between serum levels of GSH and GST after 3 weeks of receiving 1st adjuvant chemotherapy cycle (r=+0.91). The decrease in the GST activity may be associated with GST catalyzed conjugation of GSH with highly reactive electrophiles and thereby playing a major role in detoxification of chemotherapeutic drugs. The decrease in GST activity may be related with decrease in GSH after chemotherapy.

Nitric oxide is short-lived highly reactive free radical that is involved in multistep process of carcinogenesis. NO reacts spontaneously with available superoxide radical to form the more potent and versatile oxidant peroxynitrite. Peroxynitrite can damage DNA, initiate membrane lipid peroxidation, deplete antioxidant enzyme activity and reduce GSH content. In the present study, we found significantly higher levels of serum NO in post-operative breast cancer patients before undergoing adjuvant chemotherapy.
chemotherapy cycles as compare to healthy controls (P<0.0001). Some investigators have reported elevated level of nitrate and nitrite at operable stage in serum samples of patients with breast cancer 2, 16, 17, 31. Konukoglu et al. 19 have shown that serum levels of NO' increased in patients with primary breast tumor compared to controls and the values remained at high levels in post-operative breast cancer patients. Our finding is in agreement with report of Konukoglu et al. 19. It is possible that observed higher values of NO' could be due to secretion of NO' by non-immune cell types or by tumor infiltrating inflammatory cells in response to residual disease. After 3 weeks of administration of 1st cycle of adjuvant chemotherapy, we observed significant decrease in the levels of NO' as compare to levels before chemotherapy (P<0.0001) and as compare to levels in healthy controls (P<0.0001). We found a significant positive correlation between GSH and NO' after chemotherapy (r=+0.96). The observed decrease in the levels of NO' after chemotherapy may be associated with decreased levels of GSH as adequate GSH level is required for the regulation of iNOS activity by NF-κB activation and optimal synthesis of NO' 11, 12, 13. The other possible mechanism for decreased levels of NO' could be its utilization in the formation of GSNO adduct with GSH 11.

CONCLUSION
In conclusion, the findings of the study suggests that administration of chemotherapeutic drugs in adjuvant setting in breast cancer patients causes increase in oxidative stress as indicated by decreased levels of antioxidant glutathione. The observed decrease in levels of GST and NO' might be associated with decrease in levels of glutathione in these patients after chemotherapy. However, the present study is a preliminary report and more research with large study group is needed to confirm the findings. Further studies are in progress to evaluate the levels of these parameters and their relationship with apoptosis markers in different stages breast cancer patients receiving chemotherapy in adjuvant setting.

ACKNOWLEDGEMENT
Authors acknowledge the great help received from the scholars whose articles cited and included in references of this manuscript. The authors are also grateful to authors / editors / publishers of all those articles, journals and books from where the literature for this article has been reviewed and discussed. Authors are grateful to IJCRR editorial board members and IJCRR team of reviewers who have helped to bring quality to this manuscript.

REFERENCES
stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 2012;133:89-97.


20. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione-s-transferase activities in rat lung and liver. Biochim Biophys Acta 1979;582:67-78.


29. Prabasheela B, Baskaran S. Alteration of glutathione dependent enzymes in pre and post-operative breast carcinoma. JBMAS. 1-7.


Table A. 1: Serum levels of reduced glutathione, glutathione-s transferase and nitric oxide in healthy controls and stage II breast cancer patients before and after adjuvant chemotherapy.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Subjects</th>
<th>No. of cases (n)</th>
<th>Reduced Glutathione (mg/dl)</th>
<th>Glutathione-s-transferase (IU/L)</th>
<th>Nitric oxide (µmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>Healthy controls</td>
<td>30</td>
<td>3.96±1.18</td>
<td>1.81±1.21</td>
<td>33.53±5.30</td>
</tr>
<tr>
<td>Group II</td>
<td>Breast cancer patients before adjuvant chemotherapy.</td>
<td>30</td>
<td>2.84±0.42&lt;sup&gt;a&lt;/sup&gt;</td>
<td>12.58±3.9&lt;sup&gt;b&lt;/sup&gt;</td>
<td>41.16±3.8&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Group III</td>
<td>Breast cancer patients after 1&lt;sup&gt;st&lt;/sup&gt; adjuvant chemotherapy cycle.</td>
<td>30</td>
<td>1.89±0.4&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>5.33±1.54&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>24.33±4.88&lt;sup&gt;bc&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Data was expressed in terms of Mean±SD.

<sup>a</sup>P<0.0004 – Significant when compared to healthy controls.

<sup>b</sup>P<0.0001 – Significant when compared to healthy controls.

<sup>c</sup>P<0.0001 – Significant when compared to breast cancer patients before chemotherapy.